Web Results

en.wikipedia.org/wiki/Omalizumab

Omalizumab, sold under the trade name Xolair, is a medication originally designed to reduce sensitivity to allergens. It has been used to try to control severe allergic asthma, which does not respond to high doses of corticosteroids. It has been approved for treating people 12 years and older with severe or moderate to ...

www.rxlist.com/xolair-drug.htm

(omalizumab) or Injection, for Subcutaneous Use. WARNING. ANAPHYLAXIS. Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/ or angioedema of the throat or tongue, has been reported to occur after administration of Xolair. Anaphylaxis has occurred as early as after the first dose of Xolair, ...

www.medscape.com/viewarticle/494543

Results: Omalizumab is a monoclonal antibody targeting the high-affinity receptor binding site on human immunoglobulin (Ig)E. Bound IgE is not available for basophil binding, degranulation is attenuated, and allergic symptoms are reduced. In asthma trials, omalizumab reduced inhaled corticosteroid and rescue  ...

www.xolair.com/allergic-asthma/why-consider-xolair/how-xolair-works.html

XOLAIR (omalizumab) for subcutaneous use is designed to specifically block IgE. What is XOLAIR? XOLAIR® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat patients 6 years of age and older with moderate to severe persistent asthma whose asthma symptoms are not controlled by ...

www.xolair.com

XOLAIR (omalizumab) for subcutaneous use is a prescription treatment for moderate to severe persistent allergic asthma and chronic idiopathic urticaria ( CIU) in appropriate patients. What is XOLAIR? XOLAIR® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat patients 6 years of age ...

medlineplus.gov/druginfo/meds/a603031.html

Feb 15, 2015 ... Omalizumab Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus.

www.ncbi.nlm.nih.gov/pmc/articles/PMC1681435

Jan 27, 2005 ... Results. Omalizumab is a monoclonal antibody targeting the high-affinity receptor binding site on human immunoglobulin (Ig)E. Bound IgE is not available for basophil binding, degranulation is attenuated, and allergic symptoms are reduced. In asthma trials, omalizumab reduced inhaled corticosteroid and ...

www.ncbi.nlm.nih.gov/pubmed/11496232

BACKGROUND: A recombinant humanized anti-IgE mAb, omalizumab, forms complexes with free IgE, blocking its interaction with mast cells and basophils; as a consequence, it might be effective in the treatment of asthma. OBJECTIVE: The purpose of this study was to evaluate the efficacy and safety of omalizumab in the  ...

www.medicinenet.com/omalizumab/article.htm

Information about omalizumab (Xolair), an injectable drug prescribed to treat asthma that is not adequately controlled with inhaled steroids.